NCT01928329 | Yale University | Type I Diabetes | September 2013 | Phase 2 |
NCT04520490 | Seattle Children´s Hospital|University of Washington | Childhood Obesity | January 28, 2021 | Phase 3 |
NCT01104701 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes | May 2010 | Phase 2 |
NCT01077323 | AstraZeneca|Eli Lilly and Company|i3 Drug Safety | Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies)|Healthy Subjects (Treated With no Diabetes Therapies) | September 2004 | |
NCT01843127 | Gilead Sciences | Type 2 Diabetes Mellitus | April 2013 | Phase 1 |
NCT00099320 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | May 2004 | Phase 3 |
NCT02160990 | Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Obesity | June 2014 | Phase 4 |
NCT05610800 | The University of Texas Health Science Center, Houston | Smoking Cessation|Weight Gain | December 7, 2022 | Phase 2 |
NCT02325960 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Type 2 Diabetes | January 2015 | Phase 4 |
NCT01255163 | National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC) | Alzheimer´s Disease|Mild Cognitive Impairment | November 21, 2010 | Phase 2 |
NCT00517283 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | January 2005 | Phase 1 |
NCT01029886 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | January 2010 | Phase 3 |
NCT01254123 | Amsterdam UMC, location VUmc | Patients With a First Acute Myocardial Infarction to be Treated With Primary Percutaneous Coronary Intervention (PCI). | November 2009 | Phase 3 |
NCT02303730 | Fudan University|Huadong Hospital|Shanghai Minhang Central Hospital|Shanghai 6th People´s Hospital|Shanghai Changzheng Hospital | Diabetes Mellitus, Type 2|Non-alcoholic Fatty Liver Disease | March 2015 | Phase 4 |
NCT01857895 | GlaxoSmithKline|Parexel | Obesity | May 16, 2013 | Phase 1 |
NCT00353834 | Joslin Diabetes Center|Amylin Pharmaceuticals, LLC.|Eli Lilly and Company | Type 2 Diabetes Mellitus | August 2006 | Phase 4 |
NCT01588418 | The University of Texas Health Science Center at San Antonio|Amylin Pharmaceuticals, LLC. | Impaired Glucose Tolerance (IGT)|Diabetes | July 2010 | Phase 4 |
NCT02020616 | Eli Lilly and Company | Type 2 Diabetes Mellitus | December 2013 | Phase 1|Phase 2 |
NCT02432976 | Centre Hospitalier Universitaire de Besancon|AstraZeneca|Eli Lilly and Company | Quality of Life | May 2015 | Phase 2|Phase 3 |
NCT04303819 | Beijing Chao Yang Hospital | Type 2 Diabetes Mellitus in Obese | January 5, 2020 | |
NCT02467920 | Huazhong University of Science and Technology | Type 2 Diabetes Mellitus | August 2015 | Phase 4 |
NCT01484873 | Vanderbilt University Medical Center | Obesity|Overweight|Craniopharyngioma | June 2012 | Phase 2 |
NCT00064714 | AstraZeneca|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus | July 2003 | Phase 2 |
NCT05073692 | Kaiser Permanente|Geisinger Clinic|Henry Ford Health System|HealthPartners Institute|Patient-Centered Outcomes Research Institute | Type 2 Diabetes Mellitus|Cardiovascular Diseases | July 1, 2021 | |
NCT00672399 | AstraZeneca|Eli Lilly and Company | Healthy Subjects | April 2008 | Phase 1 |
NCT00835848 | Rigshospitalet, Denmark|University Hospital, Gentofte, Copenhagen | Myocardial Infarction | January 2009 | Phase 4 |
NCT00960661 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | September 2009 | Phase 3 |
NCT05482789 | Maisa N. Feghali, MD|University of Pittsburgh | Gestational Diabetes | April 12, 2023 | Phase 4 |
NCT00577824 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes | January 2008 | Phase 3 |
NCT02847403 | Azienda Ospedaliero-Universitaria di Parma | Dysglycemia|Cognitive Deficit | February 2016 | Phase 3 |
NCT02417142 | University of Massachusetts, Worcester|Stanley Medical Research Institute | Schizophrenia|Schizoaffective Disorder | September 2014 | Phase 4 |
NCT01783717 | Huashan Hospital | Hypothalamic Obesity|Diabetes Mellitus | December 2012 | Not Applicable |
NCT01969149 | Centre Hospitalier Universitaire de Besancon|AstraZeneca|Eli Lilly and Company | Stress Hyperglycemia | January 2015 | Phase 2|Phase 3 |
NCT05663515 | AstraZeneca | Pancreatic Cancer | January 1, 2024 | |
NCT03456687 | University of Florida|National Institute of Neurological Disorders and Stroke (NINDS) | Parkinson´s Disease | June 5, 2018 | Phase 1 |
NCT02650479 | Intarcia Therapeutics | Healthy Adult Male and Female Volunteers | January 2016 | Phase 1 |
NCT01089569 | HealthPartners Institute|International Diabetes Center at Park Nicollet|Sanofi | Type 2 Diabetes | April 2010 | Not Applicable |
NCT00650546 | Indiana University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Nonalcoholic Fatty Liver Disease | August 2006 | Phase 2|Phase 3 |
NCT01818648 | Mayo Clinic | Short Bowel Syndrome | March 2013 | Phase 4 |
NCT05762744 | University of Maryland, Baltimore | Type 2 Diabetes | June 1, 2016 | Phase 1 |
NCT03167411 | Theracos | Type2 Diabetes Mellitus | May 24, 2017 | Phase 1 |
NCT02690883 | Nanfang Hospital, Southern Medical University | Diabetic Nephropathies | April 8, 2016 | Phase 4 |
NCT02974244 | AstraZeneca | Type 2 Diabetes | October 28, 2014 | |
NCT04909333 | University Hospital, Basel, Switzerland|Gottfried und Julia Bangerter-Rhyner-Stiftung | Endogenous Hyperinsulinism | April 29, 2021 | Not Applicable |
NCT00753896 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes | October 2008 | Phase 3 |
NCT02975297 | The University of Texas Health Science Center, Houston | Smoking Cessation | July 2016 | Phase 1|Phase 2 |
NCT02194595 | Mount Sinai Hospital, Canada|Canadian Institutes of Health Research (CIHR)|University of Toronto | Type 2 Diabetes | September 2014 | Phase 3 |
NCT00313001 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | April 2006 | Phase 3 |
NCT03059719 | PegBio Co., Ltd. | Type II Diabetes Mellitus | April 8, 2015 | Phase 1 |
NCT01181986 | Carl T. Hayden VA Medical Center|American Diabetes Association|Amylin Pharmaceuticals, LLC. | Type 2 Diabetes Mellitus | August 2010 | Phase 4 |
NCT00782418 | Merck Sharp & Dohme LLC | The Methodology Assessment of Glucose Dependent Insulin Secretion | September 2008 | Phase 1 |
NCT02170324 | Xiang Guang-da|Wuhan General Hospital of Guangzhou Military Command | Obesity | June 2014 | Phase 4 |
NCT01373216 | Charles University, Czech Republic|Eli Lilly and Company | Coronary Artery Disease|Decreased Left Ventricular Function | June 2011 | Phase 3 |
NCT00877890 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | March 2009 | Phase 3 |
NCT01147627 | Sun Yat-sen University|Eli Lilly and Company|Amylin Pharmaceuticals, LLC.|Ministry of Health, China | Diabetes Mellitus, Type 2|Newly Diagnosed | August 2010 | Not Applicable |
NCT00254800 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | November 2005 | Phase 1 |
NCT01971242 | University College, London | Parkinson´s Disease | June 2014 | Phase 2 |
NCT00950677 | Baylor College of Medicine|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 2 Diabetes | July 2009 | Phase 4 |
NCT00882050 | Thomas Jefferson University|Amylin Pharmaceuticals, LLC.|Eli Lilly and Company | Euglycemia|Hypoglycemia|Hyperglycemia | March 2009 | Phase 1|Phase 2 |
NCT01554618 | AstraZeneca | Children and Adolescent With Type 2 Diabetes | December 2, 2011 | Phase 3 |
NCT01269034 | Albert Einstein College of Medicine|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes | December 2010 | Phase 4 |
NCT02735031 | Radboud University Medical Center|AstraZeneca | Diabetes Mellitus, Type 1|Hypoglycemia | February 21, 2017 | Phase 2|Phase 3 |
NCT03444142 | University of Guadalajara | Diabetes Mellitus, Type 2 | November 17, 2017 | Phase 4 |
NCT00500370 | AstraZeneca|Eli Lilly and Company | Obesity | June 2007 | Phase 2 |
NCT00382239 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | September 2006 | Phase 2 |
NCT01270191 | Taipei Veterans General Hospital, Taiwan | Type 2 Diabetes | November 2010 | Phase 4 |
NCT02119819 | OPKO Health, Inc. | Diabetes Mellitus, Type 2 | April 2014 | Phase 2 |
NCT02404376 | Hospital Universitari Vall d´Hebron Research Institute | ST Elevation Acute Myocardial Infarction | March 2016 | Phase 3 |
NCT01064687 | Eli Lilly and Company | Diabetes Mellitus, Type 2 | February 2010 | Phase 3 |
NCT02794402 | Uppsala University | Obesity | September 2015 | Phase 2 |
NCT01652729 | AstraZeneca | Diabetes Type 2 | February 2013 | Phase 3 |
NCT00103935 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | February 2005 | Phase 2 |
NCT00111540 | AstraZeneca | Diabetes Mellitus, Type 2 | November 2002 | Phase 3 |
NCT00516048 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | August 2007 | Phase 3 |
NCT02981069 | The University of Texas Health Science Center at San Antonio|AstraZeneca | Diabetes Mellitus, Type 2 | December 15, 2017 | Phase 4 |
NCT00359762 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | September 2006 | Phase 3 |
NCT04232969 | University College, London | Parkinson´s Disease | January 20, 2020 | Phase 3 |
NCT01208649 | Ruhr University of Bochum | Nonalcoholic Fatty Liver Disease | July 2008 | Phase 4 |
NCT01269047 | Albert Einstein College of Medicine|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes | August 2009 | Phase 4 |
NCT00886626 | University of Minnesota | Obesity, Morbid | May 2009 | Phase 2 |
NCT00456885 | Beth Israel Deaconess Medical Center|Amylin Pharmaceuticals, LLC.|Eli Lilly and Company | Obesity|Impaired Glucose Tolerance | April 2007 | Phase 4 |
NCT02690987 | Imperial College London | Obesity|Smoking Cessation|Alcoholism | August 2015 | Early Phase 1 |
NCT00082407 | AstraZeneca|Eli Lilly and Company | Diabetes Mellitus, Type 2 | November 2003 | Phase 3 |
NCT03835013 | Cambridge University Hospitals NHS Foundation Trust | Cardiovascular Diseases | February 11, 2019 | Not Applicable |
NCT01435980 | Wu Qinan|Third Military Medical University | Type 2 Diabetes | February 2008 | Phase 4 |
NCT01938235 | University Health Network, Toronto|AstraZeneca | Myocardial Infarction | February 2014 | Phase 2 |
NCT00736229 | Saint Luke´s Health System|Amylin Pharmaceuticals, LLC. | Hyperglycemia|Acute Coronary Syndromes|Myocardial Infarction | August 2008 | Phase 4 |
NCT03007329 | Medical University of Vienna|AstraZeneca | Steatosis, Liver|Type2 Diabetes | March 8, 2017 | Phase 4 |
NCT02685852 | University of Minnesota | Hyperinsulinemic Hypoglycemia | February 2016 | Phase 1 |
NCT01876849 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | December 2003 | Phase 3 |
NCT00324363 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | January 2006 | Phase 3 |
NCT00623545 | University of Wisconsin, Madison | Healthy | January 2008 | Phase 4 |
NCT02787551 | Sanofi | Type 2 Diabetes Mellitus | July 6, 2016 | Phase 3 |
NCT02344641 | Chinese Academy of Medical Sciences, Fuwai Hospital | Type 2 Diabetes Mellitus|Heart Failure | January 2015 | Not Applicable |
NCT01885208 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | December 2, 2013 | Phase 3 |
NCT01676116 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | August 29, 2012 | Phase 3 |
NCT04029272 | Peking Union Medical College Hospital | Polycystic Ovary Syndrome | July 20, 2019 | Phase 4 |
NCT03419624 | Universitätsklinikum Hamburg-Eppendorf|AstraZeneca | Obesity|Diabetes Mellitus, Type 2 | February 19, 2018 | Phase 3 |
NCT00529204 | University of California, Davis|Amylin Pharmaceuticals, LLC.|Eli Lilly and Company | Diabetes Complications|Fatty Liver | October 2007 | Phase 2 |
NCT00477581 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | May 2007 | Phase 4 |
NCT01652716 | AstraZeneca | Diabetes Mellitus, Type 2 | January 2013 | Phase 3 |
NCT02104739 | The University of Texas Health Science Center, Houston|The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston | Prediabetes|Obesity | April 2014 | Phase 4 |
NCT00241423 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | October 2005 | Phase 2 |
NCT01444898 | Children´s Hospital Los Angeles | Prader-Willi Syndrome | March 2012 | Not Applicable |
NCT02584582 | Hvidovre University Hospital | Type 1 Diabetes | July 2015 | Phase 2|Phase 3 |
NCT00082381 | AstraZeneca|Eli Lilly and Company | Diabetes Mellitus, Type 2 | June 2003 | Phase 3 |
NCT04897802 | Fundació Institut de Recerca de l´Hospital de la Santa Creu i Sant Pau|Instituto de Salud Carlos III | Hypopituitarism|Central Diabetes Insipidus|Panhypopituitarism|Psychological Disorder|Social Isolation|Hypothalamic Diseases|Pituitary Diseases|Oxytocin Deficiency | September 13, 2021 | Phase 4 |
NCT01794429 | Bjorn H. Ebdrup|University of Copenhagen | Obesity|Metabolic Syndrome X|Drug-induced Obesity|Schizophrenia | February 2013 | Phase 3 |
NCT00971659 | Profil Institut für Stoffwechselforschung GmbH|Sanofi | Type 2 Diabetes | January 2008 | Phase 1 |
NCT00845507 | University of Cincinnati|Eli Lilly and Company | Weight Gain | December 2008 | Phase 4 |
NCT00308139 | AstraZeneca | Type 2 Diabetes Mellitus | April 2006 | Phase 3 |
NCT02129985 | xiaolong zhao|Shanghai Zhongshan Hospital|The third people´s Hospital Affiliated to Shanghai Jiao Tong University|Second Affiliated Hospital of Soochow University|The First Hospital of Guiyang Medical college|Fuling Central Hospital of Chongqing City|Taizhou Hospital|Shanghai Pudong New Area Gongli Hospital|Huashan Hospital | Type 2 Diabetes | February 2014 | Phase 4 |
NCT01060059 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | April 2010 | |
NCT00766857 | Amsterdam UMC, location VUmc | Type 2 Diabetes Mellitus|Congestive Heart Failure | May 2009 | Phase 4 |
NCT00717457 | Hoffmann-La Roche | Diabetes Mellitus Type 2 | July 2008 | Phase 3 |
NCT00635492 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | January 2008 | |
NCT01501084 | University of California, Los Angeles|Amylin Pharmaceuticals, LLC. | Obesity | December 2011 | Phase 1 |
NCT01855490 | Yale University | Type 1 Diabetes | January 2012 | Phase 1 |
NCT00964262 | Peptron, Inc. | Type 2 Diabetes Mellitus | August 2009 | Phase 1 |
NCT00551343 | Garvan Institute of Medical Research | Prader-Willi Syndrome | October 2007 | Not Applicable |
NCT01174810 | University College, London | Parkinson´s Disease | July 2010 | Phase 2 |
NCT01473147 | Chang Gung Memorial Hospital | Type 2 Diabetes Mellitus | October 2011 | Not Applicable |
NCT00259896 | GlaxoSmithKline | Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2 | October 2005 | Phase 1 |
NCT02917057 | AstraZeneca | Type 2 Diabetes | August 1, 2015 | |
NCT00516074 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | September 2007 | Phase 3 |
NCT00603239 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | January 2008 | Phase 3 |
NCT00254254 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | February 2006 | Phase 2 |
NCT01416649 | University of Chicago | Type 2 Diabetes | February 1, 2011 | |
NCT03970044 | Consano Clinical Research, LLC | Diabetes Mellitus, Type 2 | July 2, 2019 | Phase 4 |
NCT02380521 | University of Palermo|AstraZeneca | Type 2 Diabetes Mellitus | January 2015 | Phase 4 |
NCT00917267 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | July 2009 | Phase 3 |
NCT05356104 | Chinese University of Hong Kong | Cerebral Small Vessel Disease | May 25, 2022 | Phase 2 |
NCT00856609 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) | Weight Loss|Obesity | March 3, 2009 | Phase 3 |
NCT00097500 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | September 2004 | Phase 3 |
NCT03671733 | Xiangya Hospital of Central South University | Obesity | September 1, 2018 | Phase 3 |
NCT03018665 | The First Hospital of Jilin University | Diabetes Mellitus, Type 2 | February 2017 | Phase 4 |
NCT02349802 | AstraZeneca|Celerion | Healthy Subjects | February 2013 | Phase 1 |
NCT02586831 | Camillo Ricordi and Jay Skyler|Diabetes Research Institute Foundation|University of Miami | Diabetes Mellitus, Type 1|Hypoglycemia|Autoimmune Diseases|Diabetes Mellitus | December 1, 2023 | Phase 1|Phase 2 |
NCT01302327 | Hadassah Medical Organization | Diabetes Mellitus Associated With Genetic Syndrome|Wolfram Syndrome | March 1, 2011 | Not Applicable |
NCT01136798 | University of Chicago | Type 2 Diabetes|Sleep Disordered Breathing | June 1, 2010 | Not Applicable |
NCT00845182 | The University of Texas Health Science Center at San Antonio | Type 2 Diabetes|Healthy|Impaired Glucose Tolerance | June 2007 | Phase 4 |
NCT00870194 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | March 2009 | Phase 4 |
NCT02313220 | Uppsala University|Uppsala University Hospital|AstraZeneca | Obesity | December 2014 | Phase 2 |
NCT00744224 | Amsterdam UMC, location VUmc|National Research Council, Institute of Biomedical Engineering | Glucocorticoid-induced Glucometabolic Abnormalities|Glucocorticoid-induced Beta-cell Dysfunction | February 2009 | Not Applicable |
NCT02118376 | Shanghai 10th People´s Hospital | Obesity | August 2014 | Not Applicable |
NCT00765817 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes | October 2008 | Phase 3 |
NCT03361098 | Amsterdam UMC, location VUmc|AstraZeneca | Type 2 Diabetes Mellitus|Obesity | September 18, 2017 | Phase 4 |
NCT03961256 | Mayo Clinic | Pre Diabetes | May 9, 2019 | Phase 2 |
NCT00855439 | University of Michigan|Amylin Pharmaceuticals, LLC.|Eli Lilly and Company | Type 2 Diabetes Mellitus|Diabetic Peripheral Neuropathy | June 2008 | Not Applicable |
NCT00775684 | University of Pennsylvania|Pennsylvania Department of Health | Pre-diabetes|Type 2 Diabetes | October 2008 | Not Applicable |
NCT01664624 | AstraZeneca | Type 2 Diabetes | July 2012 | Phase 1 |
NCT00747968 | University of Aarhus|Eli Lilly and Company|Aarhus University Hospital | Type 2 Diabetes | February 2010 | Phase 2|Phase 3 |
NCT00085969 | AstraZeneca|Eli Lilly and Company | Diabetes Mellitus, Type 2 | September 2003 | Phase 2 |
NCT02229383 | AstraZeneca | Diabetes Mellitus | September 6, 2014 | Phase 3 |
NCT00572689 | Georgetown University|Medstar Health Research Institute | Gestational Diabetes | August 2013 | Phase 4 |
NCT03232112 | Anders Fink-Jensen, MD, DMSci|The Novavì outpatient clinics, Copenhagen|Neurobiology Research Unit, Rigshospitalet, Copenhagen|Section of Biostatistics University of Copenhagen, Copenhagen|Psychiatric Centre Rigshospitalet | Alcohol Dependence, in Remission|Addiction, Alcohol | August 7, 2017 | Phase 2 |
NCT01144338 | AstraZeneca | Type 2 Diabetes Mellitus | June 18, 2010 | Phase 3 |
NCT04001231 | AstraZeneca | Type 2 Diabetes | June 30, 2020 | Phase 1 |
NCT02092597 | Charles University, Czech Republic | Type 2 Diabetes Mellitus | October 2013 | Phase 4 |
NCT04969627 | Bing He|Shengjing Hospital | Polycystic Ovary Syndrome | January 4, 2021 | Phase 4 |
NCT04305002 | Center for Neurology, Stockholm|Karolinska Institutet | Parkinson Disease | January 21, 2020 | Phase 2 |
NCT02455076 | Emory University | Type 2 Diabetes | September 2015 | Phase 4 |
NCT03297879 | Beijing Chao Yang Hospital | Type2 Diabetes | January 1, 2013 | Phase 4 |
NCT04941521 | The University of Texas Health Science Center, Houston | Cocaine Use Disorder | June 24, 2021 | Phase 1|Phase 2 |
NCT02584075 | Beijing Chao Yang Hospital | Coronary Endothelial Function | November 2015 | Phase 4 |
NCT00948168 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Type 2 Diabetes Mellitus | July 2008 | Phase 4 |
NCT00344851 | Metabolic Center of Louisiana Research Foundation|Amylin Pharmaceuticals, LLC. | Polycystic Ovary Syndrome | June 2006 | Phase 2 |
NCT01791465 | Vanderbilt University|National Institute of Allergy and Infectious Diseases (NIAID)|Vanderbilt University Medical Center | Human Immunodeficiency Virus Infection|Diabetes Mellitus | March 2013 | Phase 4 |
NCT02987348 | AstraZeneca | Type 2 Diabetes | June 30, 2015 | |
NCT01006889 | University of Florida|Amylin Pharmaceuticals, LLC. | Nonalcoholic Fatty Liver Disease|Type 2 Diabetes Mellitus | January 2008 | Phase 4 |
NCT01432405 | Baylor College of Medicine | Type 2 Diabetes Mellitus | June 2007 | Phase 4 |
NCT03029351 | University at Buffalo|AstraZeneca | Type2 Diabetes|Kidney Diseases | January 10, 2017 | Phase 4 |
NCT00667732 | Oregon Health and Science University|Amylin Pharmaceuticals, LLC.|Eli Lilly and Company | Type 2 Diabetes | March 2007 | Phase 4 |
NCT00381342 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | September 2006 | Phase 3 |
NCT03017352 | Filip Krag Knop|Steno Diabetes Center Copenhagen|University Hospital, Gentofte, Copenhagen | Diabetes Mellitus, Type 1 | December 2016 | Phase 2 |
NCT01951651 | Baylor College of Medicine | Type 2 Diabetes Mellitus | April 2010 | Phase 4 |
NCT00701935 | AstraZeneca|Eli Lilly and Company | Diabetes Mellitus | August 2008 | Phase 2 |
NCT01237197 | University of Minnesota|Children´s Hospitals and Clinics of Minnesota | Obesity | October 2010 | Phase 2 |
NCT02084654 | Stanford University | Pre Diabetes|Insulin Resistance | November 2007 | Phase 1 |
NCT00894322 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | April 2009 | Phase 1|Phase 2 |
NCT02090673 | AstraZeneca | Diabetes Mellitus Type 2 | February 2009 | |
NCT00935532 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | July 2009 | Phase 3 |
NCT00641056 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | April 2008 | Phase 3 |
NCT02664441 | Seattle Children´s Hospital|Children´s Hospitals and Clinics of Minnesota|Vanderbilt University | Hypothalamic Obesity | March 2016 | Phase 3 |
NCT00799435 | Baylor College of Medicine|National Heart, Lung, and Blood Institute (NHLBI) | Diabetes Mellitus, Type 2|Heart Failure, Diastolic | July 2009 | Phase 4 |
NCT04307797 | Cambridge University Hospitals NHS Foundation Trust|Antaros Medical | Type 2 Diabetes|Obesity | January 18, 2022 | Phase 4 |
NCT01235819 | Command Hospital, India | Type 1 Diabetes | November 2010 | Phase 4 |
NCT01140893 | University Hospital, Caen|Eli Lilly and Company | Type 2 Diabetes | November 2010 | Phase 2|Phase 3 |
NCT01580514 | Kyunghee University Medical Center | Myocardial Infarction | September 2009 | Phase 4 |
NCT00360334 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes | June 2006 | Phase 3 |
NCT01524705 | University of Washington|Eli Lilly and Company|Sanofi|Astra Zeneca, Bristol-Myers Squibb|DexCom, Inc.|Bayer|Becton, Dickinson and Company|Medicomp|University of Texas|US Department of Veterans Affairs|Biomedical Research Institute of New Mexico | Type 2 Diabetes | August 2012 | Phase 4 |
NCT00612794 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes | September 2007 | Phase 1 |
NCT00456300 | Montefiore Medical Center|National Institutes of Health (NIH) | Type 1 Diabetes | March 2007 | Phase 2 |
NCT01776788 | The First Affiliated Hospital of Xiamen University | Diabetes Mellitus, Type 2 | August 2012 | Phase 4 |
NCT02793154 | GlaxoSmithKline|Wake Forrest Baptist Health | Diabetes Mellitus, Type 2 | September 26, 2016 | Phase 4 |
NCT01154933 | University at Buffalo|Amylin Pharmaceuticals, LLC. | Type 2 Diabetes | April 2008 | Phase 2 |
NCT00872378 | Advanced Specialty Care | Morbid Obesity | February 2009 | Phase 2|Phase 3 |
NCT01003184 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | October 2009 | Phase 3 |
NCT02302976 | Yale University|National Institute on Drug Abuse (NIDA) | Cocaine Dependence | November 2014 | Phase 1 |
NCT03287076 | Neuroscience Trials Australia|National Health and Medical Research Council, Australia|Monash University | Acute Ischemic Stroke | November 23, 2017 | Phase 2 |
NCT02635386 | Woman´s|AstraZeneca | Polycystic Ovary Syndrome|Obesity | March 22, 2016 | Phase 3 |
NCT00546728 | St. Paul Heart Clinic|Amylin Pharmaceuticals, LLC.|Eli Lilly and Company|International Diabetes Center at Park Nicollet | Impaired Glucose Tolerance | October 2007 | Phase 4 |
NCT00845559 | Yale University|Amylin Pharmaceuticals, LLC. | Obesity|Insulin Resistance|Impaired Glucose Tolerance|Cardiovascular Disease | August 2008 | Phase 4 |
NCT01573806 | Seattle Children´s Hospital | Septic Shock|Inflammation|Glucose Homeostasis|Organ Dysfunction|Health-related Quality of Life | October 2012 | Phase 1|Phase 2 |
NCT00518882 | Novo Nordisk A+S | Diabetes|Diabetes Mellitus, Type 2 | August 2007 | Phase 3 |
NCT02058940 | University of North Carolina, Chapel Hill|AstraZeneca|Medtronic | Brain Injuries | August 2015 | Phase 4 |
NCT03645408 | Boston Medical Center|National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder | May 2, 2019 | Phase 1 |
NCT00707031 | Sanofi | Diabetes Mellitus, Type 2 | June 2008 | Phase 3 |
NCT02072096 | Eli Lilly and Company | Diabetes Mellitus, Type 2 | February 2014 | Phase 4 |
NCT01381926 | University of Alabama at Birmingham|Amylin Pharmaceuticals, LLC. | Type 2 Diabetes Mellitus|Bone Remodeling | February 2011 | Phase 4 |
NCT00099333 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | February 2004 | Phase 2 |
NCT00974272 | Carl T. Hayden VA Medical Center | Type 2 Diabetes Mellitus|Impaired Glucose Tolerance | August 2006 | Phase 4 |
NCT03331289 | The University of Texas Health Science Center at San Antonio|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type 2 | February 28, 2018 | Phase 4 |
NCT01988545 | Zealand University Hospital|University of Copenhagen|Glostrup University Hospital, Copenhagen | Healthy | November 2013 | Not Applicable |
NCT01744236 | Amsterdam UMC, location VUmc|EU FP7: SAFEGUARD consortium | Type 2 Diabetes | April 2013 | Phase 4 |
NCT03352869 | RenJi Hospital | Polycystic Ovary Syndrome|Overweight and Obesity|Disorder of Glucose Regulation | November 28, 2017 | Phase 4 |
NCT01364584 | University of Colorado, Denver|Amylin Pharmaceuticals, LLC.|Eli Lilly and Company | Type 2 Diabetes | October 2010 | Not Applicable |
NCT01061775 | Children´s Hospitals and Clinics of Minnesota|Amylin Pharmaceuticals, LLC. | Hypothalamic Obesity | January 2010 | Phase 1|Phase 2 |
NCT01590433 | Jody Dushay|AstraZeneca|Beth Israel Deaconess Medical Center | Obesity | March 2012 | Phase 4 |
NCT00135330 | AstraZeneca|Eli Lilly and Company | Diabetes Mellitus, Type 2 | October 2005 | Phase 3 |
NCT00637273 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | January 2008 | Phase 3 |
NCT01297062 | AstraZeneca|Eli Lilly and Company | Healthy Subjects | February 2011 | Phase 1 |
NCT00434954 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | February 2007 | Phase 3 |
NCT01056549 | University Health Network, Toronto|Eli Lilly and Company | Hyperlipidemia | January 2010 | Not Applicable |
NCT00375492 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | September 2006 | Phase 3 |
NCT00676338 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | November 2008 | Phase 3 |
NCT00943917 | Intarcia Therapeutics | Type 2 Diabetes | August 2009 | Phase 2 |
NCT02887625 | Dr. Muhammad Abdulghani|Hamad Medical Corporation | Type 2 Diabetes | February 2015 | Not Applicable |
NCT00359879 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes | September 2006 | Phase 3 |
NCT02449603 | Xijing Hospital|Air Force Military Medical University, China|First Affiliated Hospital Xi´an Jiaotong University|Second Affiliated Hospital of Xi´an Jiaotong University|Shaanxi Provincial People´s Hospital|Chang´An Hospital|Xi´an Gaoxin Hospital|Xi´an Central Hospital|Shaanxi Aerospace Hospital | Type 2 Diabetes Mellitus | November 2015 | Phase 4 |
NCT00658021 | AstraZeneca|Quintiles, Inc. | Type 2 Diabetes | May 30, 2008 | Phase 3 |
NCT01046721 | University of Nottingham | Type 2 Diabetes | September 2009 | Not Applicable |
NCT03160261 | University of Tartu | Healthy | September 7, 2017 | Phase 4 |
NCT01281228 | Amsterdam UMC, location VUmc|Eli Lilly and Company|Bristol-Myers Squibb | Diabetes Mellitus|Diabetes Mellitus, Type 2|Obesity | September 2011 | Not Applicable |
NCT00729326 | AstraZeneca|Eli Lilly and Company | Type 2 Diabetes Mellitus | August 2008 | Phase 4 |
NCT04431713 | University College, London | Multiple System Atrophy | September 16, 2020 | Phase 2 |
NCT02802514 | GlaxoSmithKline|The General Hospital Corporation d+b+a Massachusetts General Hospital | Diabetes Mellitus | September 20, 2016 | Phase 4 |